Core Insights - The Hong Kong Innovative Drug 50 ETF (513780) experienced a decline of 3.14% on October 13, with a trading volume of 478 million yuan [1] - The fund's shares decreased by 1 million, bringing the total shares to 1.831 billion, while the shares increased by 495 million over the past 20 trading days [1] - The latest net asset value of the fund is calculated at 3.339 billion yuan [1] - The performance benchmark for the fund is the CSI Hong Kong Stock Connect Innovative Drug Index return rate, adjusted for valuation exchange rates [1] - The fund is managed by Invesco Great Wall Fund Management Co., Ltd., with fund managers Jin Huang and Zhang Xiaonan [1] - Since its establishment on October 16, 2024, the fund has returned 82.35%, while the return over the past month is -6.75% [1]
10月13日港股创新药50ETF（513780）份额减少100.00万份
Xin Lang Cai Jing·2025-10-14 01:14